XML 65 R47.htm IDEA: XBRL DOCUMENT
v3.20.4

Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Disaggregation of Revenue [Line Items] |  |  |
Revenues | $ 267,908 | $ 255,765 | $ 193,919
Net investment income | 798 | 1,011 | 660
Total revenues | 268,706 | 256,776 | 194,579
Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 171,289 | 165,925 | 164,845
Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 19,655 | 19,422 | 19,055
Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 69,364 | 63,122 | 8,184
Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 7,600 | 7,296 | 1,835
Operating Segments | Pharmacy Services |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 132,663 | 130,428 | 130,012
Net investment income | 0 | 0 | 0
Total revenues | 141,938 | 141,491 | 134,736
Operating Segments | Pharmacy Services | Pharmacy network |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 85,045 | 88,755 | 87,167
Operating Segments | Pharmacy Services | Mail choice |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 56,071 | 52,141 | 47,049
Operating Segments | Pharmacy Services | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 822 | 595 | 520
Operating Segments | Pharmacy Services | Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 141,116 | 140,896 | 134,216
Operating Segments | Pharmacy Services | Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Operating Segments | Pharmacy Services | Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Operating Segments | Pharmacy Services | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 822 | 595 | 520
Operating Segments | Retail/ LTC |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 60,208 | 56,258 | 54,999
Net investment income | 0 | 0 | 0
Total revenues | 91,198 | 86,608 | 83,989
Operating Segments | Retail/ LTC | Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 70,176 | 66,442 | 64,179
Operating Segments | Retail/ LTC | Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 19,655 | 19,422 | 19,055
Operating Segments | Retail/ LTC | Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Operating Segments | Retail/ LTC | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 1,367 | 744 | 755
Operating Segments | Health Care Benefits |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 74,926 | 68,979 | 8,904
Net investment income | 483 | 599 | 58
Total revenues | 75,467 | 69,604 | 8,962
Operating Segments | Health Care Benefits | Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 164
Operating Segments | Health Care Benefits | Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Operating Segments | Health Care Benefits | Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 69,301 | 63,031 | 8,180
Operating Segments | Health Care Benefits | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 5,683 | 5,974 | 560
Corporate/ Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 111 | 100 | 4
Net investment income | 315 | 412 | 602
Total revenues | 426 | 512 | 606
Corporate/ Other | Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Corporate/ Other | Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Corporate/ Other | Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 63 | 91 | 4
Corporate/ Other | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 48 | 9 | 0
Intersegment Eliminations |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net investment income | 0 | 0 | 0
Total revenues | (40,323) | (41,439) | (33,714)
Intersegment Eliminations | Pharmacy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | (40,003) | (41,413) | (33,714)
Intersegment Eliminations | Front Store |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Intersegment Eliminations | Premiums |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | 0 | 0 | 0
Intersegment Eliminations | Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenues | $ (320) | $ (26) | $ 0

X
- Definition Premiums Earned, Net And Revenue From Contract With Customer, Excluding Assessed Tax + References No definition available. + Details
Name: | cvs_PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | cvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(2)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 + Details
Name: | us-gaap_NetInvestmentIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=cvs_PharmacyRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cvs_FrontStoreRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cvs_PremiumsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=cvs_PharmacyServicesSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=cvs_SalesChannelOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=cvs_RetailLongTermCareSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=cvs_HealthCareBenefitsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |